Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Stagg

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Cancer Research|March 8, 2012
CD73-deficient mice are resistant to carcinogenesisJohn Stagg, Paul A Beavis, Upulie Divisekera, et al.
Cancer Research|July 3, 2014
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptorDeepak Mittal, Arabella Young, Kimberley Stannard, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyJohn Stagg, Sherene Loi, Upulie Divisekera, et al.
Discover Oncology|April 20, 2026
Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breastXavier Catteau, Jean-Christophe Noël, Jennifer Fallas, et al.
Antibodies (Basel, Switzerland)|October 17, 2019
NR4A Expression by Human Marginal Zone B-CellsKim Doyon-Laliberté, Josiane Chagnon-Choquet, Michelle Byrns, et al.
Cancer Research|December 9, 2024
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine SynthesisDavid Allard, Jeanne Cormery, Salma Bricha, et al.
Journal of Translational Medicine|July 27, 2023
Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastasesRalph Saber, David Henault, Nouredin Messaoudi, et al.
Oncoimmunology|October 10, 2015
CD73: A potential biomarker for anti-PD-1 therapyPaul A Beavis, Clare Y Slaney, Nicole Milenkovski, et al.
Cancer Immunology Research|February 13, 2015
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell ResponsesPaul A Beavis, Nicole Milenkovski, Melissa A Henderson, et al.
Journal of the National Cancer Institute|October 31, 2019
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment ApproachYacine Bareche, Laurence Buisseret, Tina Gruosso, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Cancer Research|March 8, 2012
CD73-deficient mice are resistant to carcinogenesisJohn Stagg, Paul A Beavis, Upulie Divisekera, et al.
Cancer Research|July 3, 2014
Antimetastatic effects of blocking PD-1 and the adenosine A2A receptorDeepak Mittal, Arabella Young, Kimberley Stannard, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 13, 2011
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyJohn Stagg, Sherene Loi, Upulie Divisekera, et al.
Discover Oncology|April 20, 2026
Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breastXavier Catteau, Jean-Christophe Noël, Jennifer Fallas, et al.
Antibodies (Basel, Switzerland)|October 17, 2019
NR4A Expression by Human Marginal Zone B-CellsKim Doyon-Laliberté, Josiane Chagnon-Choquet, Michelle Byrns, et al.
Cancer Research|December 9, 2024
Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine SynthesisDavid Allard, Jeanne Cormery, Salma Bricha, et al.
Journal of Translational Medicine|July 27, 2023
Radiomics using computed tomography to predict CD73 expression and prognosis of colorectal cancer liver metastasesRalph Saber, David Henault, Nouredin Messaoudi, et al.
Oncoimmunology|October 10, 2015
CD73: A potential biomarker for anti-PD-1 therapyPaul A Beavis, Clare Y Slaney, Nicole Milenkovski, et al.
Cancer Immunology Research|February 13, 2015
Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell ResponsesPaul A Beavis, Nicole Milenkovski, Melissa A Henderson, et al.
Journal of the National Cancer Institute|October 31, 2019
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment ApproachYacine Bareche, Laurence Buisseret, Tina Gruosso, et al.
Pageof 11